nach oben

Journal of Interventional Cardiac Electrophysiology

Erschienen in:

03.02.2018

Rationale and design of the TRICHAMPION trial: Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy Patients

verfasst von: Antonio Berruezo, Markus Linhart, Angelo Auricchio, José Luis Zamorano, Pilar Santamaria, Roger Borràs, Felip Burgos, Josep Brugada

Erschienen in: Journal of Interventional Cardiac Electrophysiology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Dual-chamber (DDD) pacing has been used for treatment of patients with hypertrophic obstructive cardiomyopathy (HOCM). Due to inconclusive results in prior trials, current guidelines assign DDD pacing a class IIb indication in selected patients. Prior observations indicate that lack of clinical improvement may result from suboptimal effect of DDD pacing with non-physiological AV intervals due to fusion of intrinsic and paced QRS complex.

Methods

The Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy Patients (TRICHAMPION) trial is a prospective, randomized, single-blinded, multicenter study to investigate the benefit of atrial synchronous biventricular pacing (CRT-P) in highly symptomatic HOCM patients with severe left ventricular outflow tract (LVOT) obstruction who are not candidates for ablative therapies. AV node ablation is used as key tool to optimize AV intervals in patients with QRS fusion. The primary endpoint is the percentage of patients with symptomatic improvement at 12 months, defined as improvement of New York Heart Association functional class, in the Minnesota Living with Heart Failure Questionnaire score and increased cardiopulmonary exercise endurance.

Conclusions

The aim of the TRICHAMPION trial is to investigate the benefit of optimized atrial synchronous biventricular pacing in absence of QRS fusion in highly symptomatic HOCM patients with severe LVOT obstruction who are not candidates for ablative therapies.

Maron BJ. Hypertrophic cardiomyopathy: an important global disease. Am J Med. 2004;116(1):63–5. https://doi.org/10.1016/j.amjmed.2003.10.012.CrossRefPubMed

Zou Y, Song L, Wang Z, Ma A, Liu T, Gu H, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: a population-based echocardiographic analysis of 8080 adults. Am J Med. 2004;116(1):14–8. https://doi.org/10.1016/j.amjmed.2003.05.009.CrossRefPubMed

Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation. 1995;92(4):785–9. https://doi.org/10.1161/01.CIR.92.4.785.CrossRefPubMed

Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348(4):295–303. https://doi.org/10.1056/NEJMoa021332.CrossRefPubMed

Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am CollCardiol. 2005;46(3):470–6. https://doi.org/10.1016/j.jacc.2005.02.090.CrossRef

Elliott PM, Gimeno JR, Tomé MT, Shah J, Ward D, Thaman R, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J. 2006;27(16):1933–41. https://doi.org/10.1093/eurheartj/ehl041.CrossRefPubMed

McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, Dearani JA, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2007;28(21):2583–8. https://doi.org/10.1093/eurheartj/ehm117.CrossRefPubMed

Vardas PE, Auricchio A, Blanc J-J, Daubert J-C, Drexler H, Ector H, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy. The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Europace. 2007;9(10):959–98. https://doi.org/10.1093/europace/eum189.CrossRefPubMed

Agarwal S, Tuzcu EM, Desai MY, Smedira N, Lever HM, Lytle BW, et al. Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. J Am CollCardiol. 2010;55(8):823–34. https://doi.org/10.1016/j.jacc.2009.09.047.CrossRef

10.

Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation. 1994;90(6):2731–42. https://doi.org/10.1161/01.CIR.90.6.2731.CrossRefPubMed

11.

Gadler F, Linde C, Juhlin-Dannfelt A, Ribeiro A, Ryden L. Long-term effects of dual chamber pacing in patients with hypertrophic cardiomyopathy without outflow tract obstruction at rest. Eur Heart J. 1997;18(4):636–42. https://doi.org/10.1093/oxfordjournals.eurheartj.a015309.CrossRefPubMed

12.

Slade AKB, Sadoul N, Shapiro L, Chojnowska L, Simon J-P, Saumarez RC, et al. DDD pacing in hypertrophic cardiomyopathy: a multicentre clinical experience. Heart. 1996;75(1):44–9. https://doi.org/10.1136/hrt.75.1.44.CrossRefPubMedPubMedCentral

13.

Maron BJ, Nishimura RA, McKenna WJ, et al. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. J Cardiothorac Vasc Anesth. 1999;13(6):794–5. https://doi.org/10.1161/01.CIR.99.22.2927.

14.

Kappenberger L, Linde C, Daubert C, McKenna W, Meisel E, Sadoul N, et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur Heart J. 1997;18(8):1249–56. https://doi.org/10.1093/oxfordjournals.eurheartj.a015435.CrossRefPubMed

15.

Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am CollCardiol. 1997;29(2):435–41. https://doi.org/10.1016/S0735-1097(96)00473-1.CrossRef

16.

Qintar M, Morad A, Alhawasli H, Shorbaji K, Firwana B, Essali A, et al. Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy. Cochrane Database Syst Rev. 2012;(5):CD008523. https://doi.org/10.1002/14651858.CD008523.pub2.

17.

Linde C, Gadler F, Kappenberger L, Rydén L. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing In Cardiomyopathy. Am J Cardiol. 1999;83(6):903–7. https://doi.org/10.1016/S0002-9149(98)01065-0.CrossRefPubMed

18.

Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt O-A, et al. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J. 2013;34(29):2281–329. https://doi.org/10.1093/eurheartj/eht150.CrossRefPubMed

19.

Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79. https://doi.org/10.1093/eurheartj/ehu284.CrossRefPubMed

20.

Ito T, Suwa M, Sakai Y, Hozumi T, Kitaura Y. Usefulness of tissue Doppler imaging for demonstrating altered septal contraction sequence during dual-chamber pacing in obstructive hypertrophic cardiomyopathy. Am J Cardiol. 2005;96(11):1558–62. https://doi.org/10.1016/j.amjcard.2005.07.073.CrossRefPubMed

21.

Pak PH, Maughan WL, Baughman KL, Kieval RS, Kass DA. Mechanism of acute mechanical benefit from VDD pacing in hypertrophied heart: similarity of responses in hypertrophic cardiomyopathy and hypertensive heart disease. Circulation. 1998;98(3):242–8. https://doi.org/10.1161/01.CIR.98.3.242.CrossRefPubMed

22.

Sherrid MV, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. J Am CollCardiol. 2000;36(4):1344–54. https://doi.org/10.1016/S0735-1097(00)00830-5.CrossRef

23.

Sherrid MV, Pearle G, Gunsburg DZ. Mechanism of benefit of negative inotropes in obstructive hypertrophic cardiomyopathy. Circulation. 1998;97(1):41–7. https://doi.org/10.1161/01.CIR.97.1.41.CrossRefPubMed

24.

Gadler F, Linde C, Juhlin-Dannfeldt A, Ribeiro A, Ryden L. Influence of right ventricular pacing site on left ventricular outflow tract obstruction in patients with hypertrophic obstructive cardiomyopathy. J Am CollCardiol. 1996;27(5):1219–24. https://doi.org/10.1016/0735-1097(95)00573-0.CrossRef

25.

Jeanrenaud X, Schläpfer J, Fromer M, Aebischer N, Kappenberger L. Dual chamber pacing in hypertrophic obstructive cardiomyopathy: beneficial effect of atrioventricular junction ablation for optimal left ventricular capture and filling. Pacing ClinElectrophysiol. 1997;20(2 Pt 1):293–300. https://doi.org/10.1111/j.1540-8159.1997.tb06173.x.CrossRef

26.

Gadler F. Modification of atrioventricular conduction as adjunct therapy for pacemaker-treated patients with hypertrophic obstructive cardiomyopathy. Eur Heart J. 1998;19(1):132–8. https://doi.org/10.1053/euhj.1997.0561.CrossRefPubMed

27.

Rinaldi CA, Bucknall CA, Gill JS. Beneficial effects of biventricular pacing in a patient with hypertrophic cardiomyopathy and intraventricular conduction delay. Heart. 2002;87(6):e6–66. https://doi.org/10.1136/heart.87.6.e6.CrossRefPubMedPubMedCentral

28.

Berruezo A, Penela D, Burgos F, Evertz R, Fernandez-Armenta J, Roca J, et al. Optimized pacing mode for hypertrophic cardiomyopathy: impact of ECG fusion during pacing. Heart Rhythm. 2015;12(5):909–16. https://doi.org/10.1016/j.hrthm.2015.01.032.CrossRefPubMed

29.

Yufu K, Takahashi N, Ooie T, Shigematsu S, Hara M, Sako H, et al. Improved hypertrophic obstructive cardiomyopathy by left ventricular apex epicardial pacing. Intern Med. 2004;43(4):295–9. https://doi.org/10.2169/internalmedicine.43.295.CrossRefPubMed

30.

Honda T, Shono H, Koyama J, Tsuchiya T, Hayashi M, Hirayama T, et al. Impact of right atrial-left ventricular dual-chamber permanent pacing in patients with severely symptomatic hypertrophic obstructive cardiomyopathy. Circ J. 2005;69(5):536–42. https://doi.org/10.1253/circj.69.536.CrossRefPubMed

31.

Komsuoglu B, Vural A, Agacdiken A, Ural D. Effect of biventricular pacing on left ventricular outflow tract pressure gradient in a patient with hypertrophic cardiomyopathy and normal interventricular conduction. J CardiovascElectrophysiol. 2006;17(2):207–9. https://doi.org/10.1111/j.1540-8167.2005.00291.x.CrossRef

32.

Lenarczyk R, Kowalski O, Kukulski T, Kowalczyk J, Kalarus Z. Resynchronization or dyssynchronization—successful treatment with biventricular stimulation of a child with obstructive hypertrophic cardiomyopathy without dyssynchrony. J CardiovascElectrophysiol. 2007;18(5):542–4. https://doi.org/10.1111/j.1540-8167.2007.00763.x.CrossRef

33.

Berruezo A, Vatasescu R, Mont L, Sitges M, Perez D, Papiashvili G, et al. Biventricular pacing in hypertrophic obstructive cardiomyopathy: a pilot study. Heart Rhythm. 2011;8(2):221–7. https://doi.org/10.1016/j.hrthm.2010.10.010.CrossRefPubMed

34.

Marshall HJ, Griffith MJ. Ablation of the atrioventricular junction: technique, acute and long-term results in 115 consecutive patients. Europace. 1999;1(1):26–9. https://doi.org/10.1053/eupc.1998.0004.CrossRefPubMed

35.

Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation. 1999;99(22):2927–33. https://doi.org/10.1161/01.CIR.99.22.2927.CrossRefPubMed

36.

Kappenberger LJ, Linde C, Jeanrenaud X, Daubert C, McKenna W, Meisel E, Sadoul N, Chojnowska L, Guize L, Gras D, Aebischer N, Gadler F, Rydén L: Clinical progress after randomized on/off pacemaker treatment for hypertrophic obstructive cardiomyopathy. Pacing in Cardiomyopathy (PIC) Study Group. Europace 1999;1(2):77–84, DOI: https://doi.org/10.1053/eupc.1998.0024.

Titel: Rationale and design of the TRICHAMPION trial: Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy Patients
verfasst von: Antonio Berruezo
Markus Linhart
Angelo Auricchio
José Luis Zamorano
Pilar Santamaria
Roger Borràs
Felip Burgos
Josep Brugada
Publikationsdatum: 03.02.2018
Verlag: Springer US
Erschienen in: Journal of Interventional Cardiac Electrophysiology / Ausgabe 2/2018
Print ISSN: 1383-875X
Elektronische ISSN: 1572-8595
DOI: https://doi.org/10.1007/s10840-017-0306-y

Neu im Fachgebiet Kardiologie

19.04.2024 | Vorhofflimmern | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Rationale and design of the TRICHAMPION trial: Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy Patients

Abstract

Purpose

Methods

Conclusions

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Impact of the pulmonary vein orifice area assessed using intracardiac echocardiography on the outcome of radiofrequency catheter ablation for atrial fibrillation

Coronary sinus morphology in pediatric patients with supraventricular tachycardia

Successful replacement of the longest worldwide in situ Nanostim leadless cardiac pacemaker for a Micra Transcatheter Pacing System

N-3 polyunsaturated fatty acids for prevention of postoperative atrial fibrillation: updated meta-analysis and systematic review

Atrial fibrillation is associated with sudden cardiac death: a systematic review and meta-analysis

Efficacy of ultrasound-guided axillary/subclavian venous approaches for pacemaker and defibrillator lead implantation: a randomized study

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie